Arlett P - Search Results

1

Monitoring of long-term toxicities of HIV treatments: an international perspective.

Bisson G, Gross R, Miller V, Weller I, Walker A, Arlett P, Carr A, Evans S, Graham D, Justice A, Kreft-Jais C, Lundgren JD, Munk B, Murray J, Pirmohamed M, Pizzuti D, Szarfman A; Writing group. Bisson G, et al. Among authors: arlett p. AIDS. 2003 Nov 21;17(17):2407-17. doi: 10.1097/00002030-200311210-00002. AIDS. 2003. PMID: 14600511 Review. No abstract available.

2

A response to 'measles, mumps, rubella vaccine: through a glass, darkly' by Drs AJ Wakefield and SM Montgomery and published reviewers' comments.

Arlett P, Bryan P, Evans S. Arlett P, et al. Adverse Drug React Toxicol Rev. 2001 Mar;20(1):37-45. Adverse Drug React Toxicol Rev. 2001. PMID: 11395937 No abstract available.

3

A novel scheme for the reporting of adverse drug reactions.

Clarkson A, Ingleby E, Choonara I, Bryan P, Arlett P. Clarkson A, et al. Among authors: arlett p. Arch Dis Child. 2001 Apr;84(4):337-9. doi: 10.1136/adc.84.4.337. Arch Dis Child. 2001. PMID: 11259235 Free PMC article.

4

Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data.

Segec A, Slattery J, Morales DR, Januskiene J, Kurz X, Arlett P. Segec A, et al. Among authors: arlett p. Pharmacoepidemiol Drug Saf. 2021 Mar;30(3):350-359. doi: 10.1002/pds.5174. Epub 2020 Dec 8. Pharmacoepidemiol Drug Saf. 2021. PMID: 33197106 Free PMC article.

5

What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?

Januskiene J, Segec A, Slattery J, Genov G, Plueschke K, Kurz X, Arlett P. Januskiene J, et al. Among authors: arlett p. Pharmacoepidemiol Drug Saf. 2021 Mar;30(3):334-341. doi: 10.1002/pds.5162. Epub 2020 Nov 8. Pharmacoepidemiol Drug Saf. 2021. PMID: 33099846 Free PMC article.

6

Reporting adverse drug reactions in HIV infection.

Arlett PR, Lee EH, Hooker M, Darbyshire JH, Breckenridge AM. Arlett PR, et al. Genitourin Med. 1997 Oct;73(5):335. doi: 10.1136/sti.73.5.335. Genitourin Med. 1997. PMID: 9534739 Free PMC article. No abstract available.

7

The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions.

Candore G, Monzon S, Slattery J, Piccolo L, Postigo R, Xurz X, Strauss S, Arlett P. Candore G, et al. Among authors: arlett p. Drug Saf. 2022 Jan;45(1):83-95. doi: 10.1007/s40264-021-01137-0. Epub 2021 Dec 8. Drug Saf. 2022. PMID: 34881404 Free PMC article.

8

Patient Reporting in the EU: Analysis of EudraVigilance Data.

Banovac M, Candore G, Slattery J, Houÿez F, Haerry D, Genov G, Arlett P. Banovac M, et al. Among authors: arlett p. Drug Saf. 2017 Jul;40(7):629-645. doi: 10.1007/s40264-017-0534-1. Drug Saf. 2017. PMID: 28417320

9

An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance.

Pinheiro LC, Candore G, Zaccaria C, Slattery J, Arlett P. Pinheiro LC, et al. Among authors: arlett p. Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):38-45. doi: 10.1002/pds.4344. Epub 2017 Nov 16. Pharmacoepidemiol Drug Saf. 2018. PMID: 29143393 Free PMC article.

10

Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.

Pinheiro L, Blake K, Januskiene J, Yue QY, Arlett P. Pinheiro L, et al. Among authors: arlett p. Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):705-12. doi: 10.1002/pds.3998. Epub 2016 Mar 22. Pharmacoepidemiol Drug Saf. 2016. PMID: 27004571

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters